Loading
A phase 1 trial of NEO-811 run by Neomorph, Inc, now recruiting.
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma is a phase 1 interventional study registered as NCT07300241 by Neomorph, Inc, with 30 participants planned, started 2025-12-19. Conditions recorded: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC, VHL-Associated Clear Cell Renal Cell Carcinoma, VHL-Associated Renal Cell Carcinoma, Kidney Cancer Metastatic and Kidney Cancers. Interventions recorded: NEO-811.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/